Trianglezamtocabtagene autoleucel… (NCT04792489)
zamtocabtagene autoleucel (MB-CART2019.1) trial for Refractory Diffuse Large B Cell Lymphoma (DLBCL) (NCT04792489). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed/refractory large B-cell, primary or secondary CNS, mantle-cell, or Richter-transformed lymphoma. Prior-treatment requirements vary. Large B-cell cohorts require two treatment lines, or one if transplant-ineligible; mantle-cell disease requires chemotherapy and a BTK inhibitor.
The idea: collected T cells are engineered to target CD19 and CD20. After cell collection and lymphodepleting chemotherapy, patients receive one zamtocabtagene autoleucel infusion. Researchers measure response, safety, and quality of life. Previous CAR-T or bispecific T-cell therapy is excluded.
This phase 2 study plans 315 patients. Miltenyi Biomedicine sponsors; twenty-eight US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.